The results of the clinical trials conducted on Remdesivir, the antiviral by Gilead Sciences shows that the drug fails to speed the improvement of patients with COVID-19 and doesn’t not prevent them from dying. The results of this clinical trial were long-awaited.
A US company Gilead Sciences, however, has said that the data suggest that there is a “potential benefit.”
Also read: SOP to deal with COVID-19 patients
According to reports, a draft document was accidentally posted on the website of the WHO and was removed later. It is unclear why this was done
Gilead spokesperson Amy Flood told the media that according to the company, the post on WHO’s website mischaracterised the study.
